Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2012-11-17 Director's Dealing
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
FORM 4 -
Director's Dealing
2012-11-17 English
FORM 4 -
Director's Dealing
2012-11-07 English
FORM 4
Director's Dealing
2012-11-05 English
10-Q
Interim / Quarterly Report 9M 2012
2012-10-31 English
THERAVANCE, INC. 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 30, 2012, reporting the results of operations and financial condition for the quarter ended September 30, 2012. It includes a press release as Exhibit 99.1 with financial results. The text states that the information is being furnished and is not "filed" for Section 18 purposes, indicating it is an earnings release rather than a full quarterly report. The document length is short (2751 characters), and it primarily announces financial results for a quarter, consistent with an Earnings Release (ER).
2012-10-30 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions an event on October 24, 2012, where GlaxoSmithKline presented a poster at a medical conference. The document includes an exhibit of the poster and is signed by the CFO. There is no detailed financial data, earnings information, or comprehensive report content. The length is 3401 characters, which is relatively short and consistent with a current report rather than a full financial report. The content is an announcement of an event and related exhibit, fitting the nature of an 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like 8-Ks that do not fit other specific categories.
2012-10-24 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.